IFRX

InflaRx NV (IFRX)

InflaRx NV

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:IFRX

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/06	06 : 07	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IFRX	InflaRx NV
2024/06/06	01 : 00	GlobeNewswire Inc.	InflaRx Hosts R&D Event Highlighting the Promise of INF904	NASDAQ:IFRX	InflaRx NV
2024/05/22	05 : 15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IFRX	InflaRx NV
2024/05/22	03 : 30	GlobeNewswire Inc.	InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators	NASDAQ:IFRX	InflaRx NV
2024/05/08	21 : 43	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IFRX	InflaRx NV
2024/05/08	20 : 30	GlobeNewswire Inc.	InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:IFRX	InflaRx NV
2024/04/30	20 : 30	GlobeNewswire Inc.	InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024	NASDAQ:IFRX	InflaRx NV
2024/04/24	20 : 30	GlobeNewswire Inc.	InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event	NASDAQ:IFRX	InflaRx NV
2024/03/21	20 : 00	GlobeNewswire Inc.	InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans	NASDAQ:IFRX	InflaRx NV
2024/03/19	20 : 30	GlobeNewswire Inc.	InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024	NASDAQ:IFRX	InflaRx NV
2024/02/22	21 : 30	GlobeNewswire Inc.	InflaRx Appoints Jan Medina as Head of Investor Relations	NASDAQ:IFRX	InflaRx NV
2024/01/25	22 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IFRX	InflaRx NV
2024/01/25	21 : 30	GlobeNewswire Inc.	InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients	NASDAQ:IFRX	InflaRx NV
2024/01/05	06 : 16	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IFRX	InflaRx NV
2024/01/04	21 : 00	GlobeNewswire Inc.	InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904	NASDAQ:IFRX	InflaRx NV
2023/11/06	22 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IFRX	InflaRx NV
2023/11/06	21 : 30	GlobeNewswire Inc.	InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum	NASDAQ:IFRX	InflaRx NV
2023/11/01	21 : 04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IFRX	InflaRx NV
2023/11/01	20 : 30	GlobeNewswire Inc.	InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update	NASDAQ:IFRX	InflaRx NV
2023/09/11	21 : 45	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IFRX	InflaRx NV
2023/09/11	20 : 00	GlobeNewswire Inc.	InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904	NASDAQ:IFRX	InflaRx NV
2023/08/30	21 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IFRX	InflaRx NV
2023/08/30	20 : 30	GlobeNewswire Inc.	InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)	NASDAQ:IFRX	InflaRx NV
2023/08/10	21 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IFRX	InflaRx NV
2023/08/10	20 : 30	GlobeNewswire Inc.	InflaRx Reports Second Quarter 2023 Financial Results & Operating Update	NASDAQ:IFRX	InflaRx NV
2023/07/13	05 : 01	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:IFRX	InflaRx NV
2023/07/12	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:IFRX	InflaRx NV
2023/07/01	05 : 06	Edgar (US Regulatory)	Form F-3 - Registration statement by foreign private issuers	NASDAQ:IFRX	InflaRx NV
2023/06/28	21 : 31	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:IFRX	InflaRx NV
2023/06/28	21 : 30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IFRX	InflaRx NV